Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Тирзепатид для лечения обструктивного апноэ сна и ожирения
Susan S Redline, Ingo Fietze, Atul Malhotra, Ronald R. Grunstein, Julia P. Dunn, Ali Azarbarzin, Richard J. Schwab, Mathijs C. M. Bunck, Josef Bednařík, Ingo Fietze, Terri E. Weaver, Scott A. Sands, Richard J Schwab, Sujatro Chakladar, Ali Azarbarzin
2024-06-21

apnea-hypopnea indexobstructive sleep apneaphase 3 randomized controlled trialspositive airway pressuretirzepatide
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
1
Among participants not receiving positive airway pressure, tirzepatide reduced AHI by 25.3 events per hour versus 5.3 with placebo, with a treatment difference of -20.0 events per hour (P<0.001).
2
Among participants receiving positive airway pressure, tirzepatide reduced AHI by 29.3 events per hour versus 5.5 with placebo, with a treatment difference of -23.8 events per hour (P<0.001).
3
In two phase 3 randomized trials, tirzepatide substantially reduced apnea-hypopnea index (AHI) after 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea.
4
Tirzepatide was associated with significant improvements in prespecified secondary outcomes, including percent changes in AHI and body weight, hypoxic burden, patient-reported sleep impairment and disturbance, hsCRP concentration, and systolic blood pressure.

Adults with moderate-to-severe obstructive sleep apnea and obesity, with or without baseline positive airway pressure therapy

The effects of tirzepatide treatment on sleep-apnea severity, body weight, hypoxic burden, patient-reported sleep impairment, inflammation, and systolic blood pressure

Publication Details
Publication Date
2024-06-21
Journal
Publisher
ISSN
Cited by
980
Access Type
Author Information
Authors
Susan S Redline
Ingo Fietze
Atul Malhotra
Ronald R. Grunstein
Julia P. Dunn
Ali Azarbarzin
Richard J. Schwab
Mathijs C. M. Bunck
Josef Bednařík
Ingo Fietze
Terri E. Weaver
Scott A. Sands
Richard J Schwab
Sujatro Chakladar
Ali Azarbarzin
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%